Article
Biochemistry & Molecular Biology
Duaa Alkaabi, Kholoud Arafat, Shahrazad Sulaiman, Aya Mudhafar Al-Azawi, Samir Attoub
Summary: Triple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer with poor prognosis. This study investigated the role of programmed death-ligand 1 (PD-L1) in TNBC MDA-MB-231 cells independent of its binding to PD-1 receptors on T cells. The study found that knockout of PD-L1 inhibited cell proliferation, colony formation, migration, and invasion in vitro, as well as tumor growth in a chick embryo model in vivo. PD-L1 knockout also affected the expression of several downstream proteins involved in tumor progression. These findings suggest that targeting PD-L1 could be a potential therapeutic strategy for TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Krishnendu Ghosh, Samarendranath Ghosh, Uttara Chatterjee, Pritha Bhattacharjee, Anirban Ghosh
Summary: The study finds that in glioma, proliferation is high in lower grades (LG) supported by VEGF-dependent angiogenesis maintenance, while this angiogenesis decrease is unlikely in higher grades (HG). On the other hand, invasion associated with MMP 2 and 9 is increased in HG, along with a dominant presence of CD204(+) M2 polarized macrophages and a general increase in global DNMT1-associated methylation.
CELLULAR AND MOLECULAR NEUROBIOLOGY
(2022)
Article
Cell Biology
Kuan-bing Chen, Wei Yang, Ying Xuan, Ai-jun Lin
Summary: This study found that miR-526b-3p can reverse cisplatin resistance in lung cancer, suppress metastasis, and activate CD8+ T cells, providing a new clue to improve the anti-tumor effects of combining immunotherapy and chemotherapy.
CELL DEATH & DISEASE
(2021)
Article
Cell & Tissue Engineering
Qing Zhang, Junwen Zhang, Peiwen Wang, Guidong Zhu, Guishan Jin, Fusheng Liu
Summary: The study found that glioma-associated mesenchymal stem cells (GA-MSCs) have the potential to induce upregulation of programmed death ligand 1 (PD-L1) in glioma cells and are involved in vascular mimicry. Importantly, oncolytic Ad5-Ki67/IL-15 reduced PD-L1 expression in glioma cells and neovascularization by targeting GA-MSCs. Furthermore, despite the presence of GA-MSCs, the virus showed potent antitumor efficacy in vitro and in vivo.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Cell Biology
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang
Summary: CFI is overexpressed in glioma and is associated with poor outcomes, serving as a potential prognostic biomarker and driving malignant progression in glioma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Thamiris Becker Scheffel, Nathalia Grave, Pedro Vargas, Fernando Mendonca Diz, Liliana Rockenbach, Fernanda Bueno Morrone
Summary: Glioblastoma is a highly malignant subtype of glioma, and the immune landscape within the tumor microenvironment plays a crucial role in influencing therapy outcomes. The presence of multiple immunosuppression pathways, particularly the adenosine pathway, poses significant obstacles to immune-based cancer therapies and can contribute to treatment resistance. Research focusing on immune checkpoints and the adenosine pathway may provide insights into potential targets for improving tumor treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Qi Tian, Tong Wu, Xiudi Zhang, Ke Xu, Xiaobo Yin, Xiaojie Wang, Shanshan Shi, Ping Wang, Liming Gao, Shufeng Xu, Xinyan Liu
Summary: This study found that circ_001678 acts as a sponge to up-regulate ZEB1 expression, inducing PD-1/PD-L1 pathway-dependent immune escape and promoting malignant progression of NSCLC.
HUMAN MOLECULAR GENETICS
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
R. Laudicella, N. Quartuccio, G. Argiroffi, P. Alongi, L. Baratto, E. Califaretti, V Frantellizzi, G. De Vincentis, A. Del Sole, L. Evangelista, S. Baldari, S. Bisdas, Francesco Ceci, Andrei Iagaru
Summary: The current use of non-amino acid PET radiopharmaceuticals for assessing perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological features in glioma patients is limited. Further exploration of investigational PET radiopharmaceuticals and studies validating their potential are necessary for clinical translation in glioma assessment.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Oncology
Xin Guo, Yuelin Zhang, Hengxing Jiao, Xingyu Miao
Summary: PD-L1 expression is significantly associated with low overall survival (OS) in patients with glioblastoma (GBM). However, this result needs to be interpreted with caution and further evaluated in large, multicenter clinical studies with similar baseline data.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Ming Yi, Xiaoli Zheng, Mengke Niu, Shuangli Zhu, Hong Ge, Kongming Wu
Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.
Article
Multidisciplinary Sciences
Reza Mirzaei, Ashley Gordon, Franz J. Zemp, Mehul Kumar, Susobhan Sarkar, H. Artee Luchman, Anita C. Bellail, Chunhai Hao, Douglas J. Mahoney, Jeff F. Dunn, Pinaki Bose, V. Wee Yong
Summary: The study identified a population of cells coexpressing PD-1 and BTIC marker within the human glioblastoma microenvironment, with tumor-intrinsic PD-1 promoting proliferation and self-renewal of BTICs independently of PD-L1. Additionally, BTIC-intrinsic PD-1 accelerated intracranial tumor growth in mice lacking T and B cells, indicating a nonimmune resistance mechanism to PD-1 or PD-L1-blocking therapies in patients with glioblastoma.
Article
Immunology
Li -Chong Wang, Yue-Long Wang, Bin He, Yan-Jiang Zheng, Hong-Chi Yu, Zhi-Yong Liu, Rang-rang Fan, Xin Zan, Rui-Chao Liang, Ze-Pei Wu, Xin Tang, Guo-Qing Wang, Jian-Guo Xu, Liang-Xue Zhou
Summary: Immune checkpoint therapy has shown breakthrough in cancer treatment, but its interaction in glioma remains controversial. In this study, we analyzed transcriptome data and conducted immunofluorescence assay to detect the features of immune checkpoints. We found that B7-H3, VISTA, and PD-L1 were associated with overall survival and grade in glioma.
CLINICAL IMMUNOLOGY
(2022)
Review
Immunology
Yi-Fan Zeng, Xin-Yu Wei, Qi-Hao Guo, Si-Yu Chen, Sheng Deng, Zheng-Zheng Liu, Zhi-Cheng Gong, Wen-Jing Zeng
Summary: This meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in glioma patients. A total of 20 studies involving 2,321 patients were included. The results showed that PD-1/PD-L1 inhibitors did not significantly improve overall survival (OS) and progression-free survival (PFS), but had a certain efficacy in terms of 6-month, 1-year, and 2-year OS. Furthermore, PD-1/PD-L1 inhibitors were associated with a relatively high incidence of adverse events (70%).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell & Tissue Engineering
Wei Chen, Ming Wu, Si-Tong Cui, Yue Zheng, Zhen Liu, Liang-Sheng Luo
Summary: In this study, it was shown that circ-ITCH is significantly downregulated in glioma and can inhibit cell proliferation and invasion by regulating the miR-106a-5p/SASH1 axis, providing a new molecular target for glioma treatment.
CELL TRANSPLANTATION
(2021)
Article
Oncology
Xuezhu Chen, Yuhong Li, Chenghai Zuo, Kaiyuan Zhang, Xuejiao Lei, Ju Wang, Yang Yang, Jianmin Zhang, Kang Ma, Shi Wang, Ning Mu, Chuanyan Yang, Jishu Xian, Hua Feng, Rongrui Tang, Tunan Chen
Summary: Research shows that lncRNA H19 promotes proliferation, invasion, and migration of glioma cells through the H19/miR-200a/CDK6/ZEB1 axis, with miR-200a playing a key role in reversing H19-induced malignant behavior. This novel signaling pathway may hold promise for the diagnosis and targeted treatment of glioma.
FRONTIERS IN ONCOLOGY
(2021)
Review
Plant Sciences
Kai-Jun Gou, Rui Zeng, Yue Ma, Ai-Nuan Li, Kai Yang, Heng-Xiu Yan, Shen-rui Jin, Yan Qu
JOURNAL OF ETHNOPHARMACOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Shuzhen Li, Ye Deng, Zhujun Wang, Zhaojing Zhang, Xiao Kong, Wenjun Zhou, Yanyun Yi, Yuanyuan Qu
MOLECULAR ECOLOGY RESOURCES
(2020)
Article
Ophthalmology
Minghang Pei, Chan Zhao, Fei Gao, Yi Qu, Anyi Liang, Junyan Xiao, Meifen Zhang
Summary: Behcet's uveitis (BDU) patients exhibit significant changes in retinal vascular imaging, with potential risk factors for visual impairment. During unilateral BDU attacks, the degree of capillary reduction in the fellow eye correlates with the severity of the ocular disease.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2021)
Article
Hematology
Xin Li, Zi Sheng, Yuanxin Sun, Yuanjian Wang, Miao Xu, Zhiyue Zhang, Hui Li, Linlin Shao, Yanqi Zhang, Jinming Yu, Chunhong Ma, Chengjiang Gao, Ming Hou, Heyu Ni, Jun Peng, Ji Ma, Qi Feng
Summary: The expression of HLA-G and immunoglobulin-like transcripts is found to be impaired in patients with ITP. Recombinant HLA-G can correct this abnormality by upregulating immunoglobulin-like transcripts, stimulating Th2 differentiation, and downregulating Th1 and Th17 immune responses, suggesting that HLA-G can be a potential diagnostic marker and therapeutic option for ITP.
Review
Pediatrics
Pradhan Rina, Yan Zeng, Junjie Ying, Yi Qu, Dezhi Mu
EUROPEAN JOURNAL OF PEDIATRICS
(2020)
Article
Chemistry, Multidisciplinary
Dong-Qing He, Hong-Cheng Liu, Qi Wang, Qian Yu, Jin-Ying Liu, Yun-Peng Qu, Xiao-Chen Zhang
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
(2020)
Review
Medicine, General & Internal
Xia Qiu, Huiqing Wang, Ying Tang, Xiaojuan Su, Long Ge, Yi Qu, Dezhi Mu
ANNALS OF MEDICINE
(2020)
Review
Food Science & Technology
Yan Yue, Wenxing Li, Jun Tang, Yan Zeng, Tao Xiong, Xia Qiu, Jing Shi, Hua Wang, Bin Xia, Lili Luo, Yi Qu, Dezhi Mu
Summary: Maternal consumption of caffeine is associated with a higher risk of certain birth defects, particularly cardiovascular, craniofacial, alimentary tract, and abdominal-wall defects. No association was found with musculoskeletal, genitourinary, or nervous system defects. Categories of caffeine intake (low, moderate, and high) were all linked to increased risks of cardiovascular and alimentary tract defects.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2021)
Article
Neurosciences
Xue Fan, Huiqing Wang, Li Zhang, Jun Tang, Yi Qu, Dezhi Mu
Summary: The neonatal brain is vulnerable to hypoxic-ischemic injury due to decreased perfusion of oxygen and glucose, which can lead to severe encephalopathy. Early therapeutic hypothermia may provide neuroprotection, but cannot reverse severe damage that has already occurred. Therefore, exploring mechanisms for treating hypoxic-ischemic brain damage, such as hypoxic/ischemic preconditioning, is crucial for protecting the neonatal brain.
REVIEWS IN THE NEUROSCIENCES
(2021)
Article
Infectious Diseases
Dongqiong Xiao, Xihong Li, Xiaojuan Su, Dezhi Mu, Yi Qu
Summary: This article discusses the transmission of novel coronavirus from humans to humans, the role of ACE2 in the pathogenesis of ARDS and acute lung injury, and the potential of vitamin D in modulating ACE2 to alleviate the symptoms induced by the virus.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Letter
Oncology
Yanming Wang, Tianshu Yu, Qiaofeng Dong, Shuang Liu, Yafei Yu, Hong Yu Zhao, Ji Ma, Lin Dong, Liang Wang, Daoxin Ma, Yajing Zhao, Yu Hou, Xinguang Liu, Jun Peng, Ming Hou
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Jing Qin, Qiang Liu, Anli Liu, Shaoqiu Leng, Shuwen Wang, Chaoyang Li, Ji Ma, Jun Peng, Miao Xu
Summary: The study found that in immune thrombocytopenia (ITP), the metabolism of CD4(+) T cells shifts from oxidative phosphorylation to glycolysis. Empagliflozin can affect the differentiation of CD4(+) T-cell subsets and regulate metabolic reprogramming in CD4(+) T cells. These findings suggest that empagliflozin may be a potential therapeutic option for ITP.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Meeting Abstract
Hematology
Ji Ma, Qiang He, Ke Lu, Liang Wang
Article
Biochemistry & Molecular Biology
Wenjun Wu, Pin Lu, Priyal Patel, Ji Ma, Kathy Qi Cai, Vinay S. Mallikarjuna, Sahar Poureghbali, Shazia R. Nakhoda, Reza Nejati, Y. Lynn Wang
Summary: Loss of SHP1 can serve as an alternative biomarker to identify patients who potentially benefit from ibrutinib treatment, and reducing SHP1 pharmacologically may represent a new strategy to augment tumor response to BCR-directed therapies.
Article
Oncology
Ji Ma, Xiaoyue Wang, Hui Lu, Zhihao Liang, Liang Wang
Summary: POEMS syndrome, a rare monoclonal plasma cell disorder, currently lacks a unified treatment. This study conducted a meta-analysis and found that Ixazomib combined with ASCT therapy may be a safe and effective treatment method.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
